Learn how to shorten the drug discovery design-make-test-analyze cycle with D360 Blog Post
研究者はD360を使用することで、異なるデータソースにまたがる研究データを効率的に検索・抽出し、小分子および生物学的薬剤の両方に関する視覚化な解析を行うことができます。その結果Our industry-leading software D360 enables…
The Utility of Model-Informed Drug Development for Rare Diseases Blog Post
モデルを活かした医薬品開発（MIDD）は、密接に統合されたエコシステムのネットワークであり、不確実性を最小限に抑えながら、新薬候補をシームレスに位置づけることができます。Indeed, MIDD affords…
Certara Earns 2022 Great Place to Work Certification™ Blog Post
Princeton, NJ, 2022年5月17日. Certara, Inc., a global leader in biosimulation, today announced that the Company was Certified™ by Great Place to Work® in its first year of participation. …
Ask Me Anything: Career Opportunities in Regulatory & Medical Writing Blog Post
Have you ever wondered what it would be like to be a Regulatory or Medical Writer in the pharmaceutical industry? Certara’s global regulatory writing team includes PhDs, MDs, PharmDs, scientists,…
Project Optimus Resource Portal Page
Project Optimus Resource Portal With the evolving regulatory landscape in oncology, we know that it is critical to stay on top of the latest news and be informed. 当社のグロー...
Approaches to Address the Regulatory Requirements for System Qualification of the Simcyp Simulator Blog Post
Physiologically-based pharmacokinetic (PBPK) modeling is being increasingly used in drug development to avoid unnecessary clinical drug–drug interaction (DDI) studies and inform drug labels. Thus, regulatory agencies are recommending more rigorous…
